glp-1 lupus weight-loss-medicines-lupus-ozempic-wegovy-mounjaro-zepbound GLP-1 Receptor Agonists Reduce Cardiovascular
Description
The cardiovascular outcomes trial SUSTAIN-6, led by Steven Marso, demonstrated reduced major adverse cardiovascular events in patients with diabetes and high cardiovascular risk on semaglutide an important signal for long-term benefit beyond weight reduction
and you weren't the problem." This shift in understanding opens the door to more comprehensive care
doi: 10.1016/j.esmoop.2021.100315 17 MascoloAScavoneCFerrajoloCRafanielloCDanesiRDel ReMet al
10.1007/s00592-018-1271-3 173 ShahZ.KampfrathT.DeiuliisJ
